TOP CONTRIBUTORS

Grant Zeng

ALNY AT A GLANCE

P/E ► -28.0   EV/EBITDA ► -46.9   ROA ► -6.2% AVG ROE ► -16.4% AVG Debt to Equity ► 1.79 AVG Current Ratio ► 4.02 AVG Interest Coverage Ratio ► -48.6 AVG

 

 

 

 

 

 

Revenue, Net Income, and Net MarginRevenue, Gross Profit, and Gross MarginOperating IncomeEbitIncome Before TaxesNet Income from Continuing OpsInterest vs Continuing IncomeInterest CoverageOperating Expenses Research & DevelopmentSG&AAmortization & Depreciation

Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi. Alnylam founders pioneered the discovery of RNAi, and now the company is utilizing this technology to build an early-stage pipeline of drug products to treat a wide array of diseases. Key programs in the area of respiratory syncytial virus (RSV), Parkinson's disease (PD), cystic fibrosis (CF), and spinal cord injury round out the company s core focus. Alnylam generates revenues from research collaborations, grants, and licensing of the RNAi technology outside its core focus area. Alnylam has partnered with many big pharmas and large organizations, such as Novartis, Roche, Medtronic, The Mayo Clinic, the Cystic Fibrosis Foundation, and Isis Pharmaceuticals, to help fund preclinical and clinical work. Alnylam pronounced (al-NIGH-lam) went public in the second quarter of 2004. The company is headquartered in Cambridge, MA.

Along with Isis, Alnylam has spun of Regulus Therapeutics, which focuses on harnessing microRNAs for the treatment of various diseases. Regulus has partnered with GlaxoSmithKline to develop anti-inflammatory therapeutics.

[edit] References